Pulsatile insulin Pulsatile insulin Pulsatile intravenous insulin therapy, sometimes called metabolic activation therapy, or cellular activation therapy describes in a literal sense the intravenous injection of insulin in pulses versus continuous infusions. Injection of insulin in pulses mimics the physiological secretions of insulin by the pancreas into the portal vein which then drains into the liver. In healthy, non-diabetic individuals, pancreatic secretions of insulin correspond to the intake of food. The pancreas will secrete variable amounts of insulin based upon the amount of food consumed (basically speaking, the more food that is consumed, the more insulin the pancreas will secrete) among other
Brockmann body inhibiting glucagon. Somatostatin released from Brockmann body inhibits cells to produce insulin and glucagon. In addition it inhibits release of growth hormone from the pituitary. It is named after a German physician Heinrich Brochmann who discovered it in 1848. Brochmann body has gained a new attention in medical research, specifically in the management of type I diabetes mellitus. This is because the tissue is easy to harvest, and its insulin can be easily extracted. In addition, the teleost fishes can regenerate their endocrine tissues after harvest, the property of which has challenging implication in human diabetes. A typical Brochmann body